Google
CGEM — CULLINAN ONCOLOGY LLC (Healthcare >> Biotechnology)
CGEM FAQ
What is CGEM's ROE?
CULLINAN ONCOLOGY LLC reports a Return on Equity (ROE) of -60.36%.
What is CGEM's dividend yield?
CULLINAN ONCOLOGY LLC offers a dividend yield of 0.00%.
What is CGEM's Deepscope Quality Score?
Deepscope rates CGEM's overall financial quality at 8 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CGEM?
Deepscope's AI Timing Score for CGEM is 70 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CGEM belong to?
CULLINAN ONCOLOGY LLC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 13.51
Price
-0.92
(-6.38%)
Day Change
|
|
|---|
CGEM, the overall quality is not good ( Quality = 8) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 13.51 |
| PBV / Sector |
2.27 / 4.63
|
| Earning Per Share | -3.60 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
15.58 M
GREAT
|
| Average 1W Daily Value |
14.11 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:29 |
| Symbol | CGEM |
| Name | CULLINAN ONCOLOGY LLC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 61.46 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 830.30 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: One Main Street, Cambridge, MA, United States, 02142
Phone: 617 410 4650
Website: https://cullinantherapeutics.com
Employees: 109
Sector: Healthcare >> Biotechnology
Description: Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
